Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone for trigeminal neuralgia and chronic migraine
IRCT20171109037332N2Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of naltrexone in trigeminal neuralgia (TN) and chronic migraine (2 cohorts), sponsored by Kerman University of Medical Sciences. Primary endpoints: Rate of recovery of chronic pain, Daily pain intensity and 1 more. Started May 2022; status: completed.
02
Drugs
naltrexone
03
Conditions
trigeminal neuralgia (TN)chronic migraine
Beyond the preview
Go deeper on IRCT20171109037332N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171109037332N2.